Today’s Highlights- Prohost Biotech - Exclusive Biotech Research

Category: Today’s Highlights

Lexaria Bioscience Unveils Extensive Planned 2024 GLP-1 Study Program

Lexaria Bioscience Extensive Program Designed to Support Commercial Discussions. January 16, 2024, Lexaria Bioscience ( LEXX ) announced a comprehensive planned applied research program to thoroughly evaluate DehydraTECH for the improved delivery of GLP-1 drugs, designed to support prospective commercial...

January 16, 2024

Ionis Pharmaceuticals: Positive Results from Phase 3 OASIS-HAE Study of Investigational Donidalorsen for Hereditary Angioedema

Ionis Pharmaceuticals in the NEWS Ionis Pharmaceuticals ( IONS ) today announced positive topline results for the Phase 3 OASIS-HAE study of donidalorsen in people with hereditary angioedema ( HAE ). The trial met its primary endpoint of reduction in...

January 22, 2024

Preclinical Studies Demonstrate Sotrovimab Retains Activity Against the Full Combination of Mutations in the Spike Protein of the Omicron Variant

GlaxoSmithKline and Vir Biotechnology Sotrovimab Retains In Vitro Activity Against Omicron GlaxoSmithKline plc ( GSK ) and Vir Biotechnology ( VIR ) announced an update to preclinical data on bioRxiv1 - a preprint server, demonstrating that sotrovimab - an investigational monoclonal antibody,...

December 7, 2021

Madrigal Pharmaceuticals Announces U.S. Availability of its Newly Approved Product Rezdiffra

Madrigal Pharmaceuticals in the NEWS Today, April 09, 2024, Madrigal Pharmaceuticals ( MDGL ) announced that its NASH MASH product Rezdiffra ( resmetirom ) is now available in the United States. Rezdiffra is indicated in conjunction with diet and exercise...

April 9, 2024

Celldex Therapeutics Dosed the First Patient in a Phase 1 Study of CDX-0159 for Prurigo Nodularis

Celldex Therapeutics Dosed the First Patient with CDX-0159 for Prurigo Nodularis Celldex Therapeutics ( CLDX ) announced that the first patient in a Phase 1 study of CDX-0159 for prurigo nodularis ( PN ) has been already dosed. From Celldex...

December 8, 2021

Vera Therapeutics Presents Positive 72-Week Data Showing eGFR Stabilization in the Phase 2b ORIGIN Clinical Trial OLE in IgA Nephropathy

Vera Therapeutics Positive Data Announcement Vera Therapeutics ( VERA ) announced positive 72-week data from the open label extension ( OLE ) period of its Phase 2b ORIGIN clinical trial of atacicept in participants with IgA nephropathy ( IgAN )....

January 25, 2024

AstraZeneca Granted FDA EUA for Long Acting Antibody Evusheld for Pre-Exposure Prophylaxis of Covid-19

AstraZeneca Long Acting Antibody Granted FDA EUA for COVID-19 Prevention AstraZeneca ( AZN ) product Evusheld (tixagevimab co-packaged with cilgavimab), a long-acting antibody ( LAAB ) combination received emergency use authorization ( EUA ) in the US for the pre-exposure...

December 9, 2021

Vertex Pharmaceuticals Announces Advancements of Its Product Suzetrigine for Acute and Neuropathic Pain

Vertex Pharmaceuticals in the NEWS Vertex Pharmaceuticals ( VRTX ) announced advancements across its suzetrigine pain program, which has the potential to be the first new class of medicine for acute and neuropathic pain in more than two decades. Vertex’s...

April 18, 2024

Vertex Pharmaceuticals Announced Positive Results from its Non-Opioid Product VX-548

Vertex Pharmaceuticals Positive Results for VX-548 Today, Vertex Pharmaceuticals ( VRTX ) announced positive results from its Phase 3 program for the treatment of moderate-to-severe acute pain. The Phase 3 program included two randomized, double- blind, placebo-controlled, pivotal trials, one...

January 30, 2024

Arcturus Therapeutics Additional Updates from ARCT-154 and ARCT-165 Clinical Trials and More

Arcturus Therapeutics Holdings Arcturus Therapeutics Holdings ( ARCT ) is a clinical-stage mRNA medicines company of enabling technologies with an interesting pipeline of treatments and vaccines as well as other products for diseases that have yet to find treatments. Arcturus Therapeutics’...

December 16, 2021

Search ProhostBiotech

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis

September 19, 2024

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024